New combo shows promise for tough bile duct cancer
NCT ID NCT03785873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of an immunotherapy drug (nivolumab) and chemotherapy drugs (nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin) in 34 people with advanced biliary tract cancer that had worsened after initial treatment. The goal was to see if the combo could shrink tumors or slow cancer growth. While not a cure, the approach aims to give patients more time and better control over the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49503, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
-
Virginia Mason
Seattle, Washington, 98101, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers